A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial
Phase of Trial: Phase III
Latest Information Update: 12 Jul 2017
At a glance
- Drugs Grazoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 21 Jun 2017 Planned End Date changed from 23 Aug 2021 to 13 May 2022.
- 21 Jun 2017 Planned primary completion date changed from 23 Aug 2021 to 13 May 2022.
- 04 Apr 2017 This trial has been completed in Czech Republic as per European Clinical Trials Database record.